07:00 , Sep 4, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Ophthalmic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Ophthalmic disease Glaucoma; optic neuropathy Gap junction protein d2 36 kDa (GJD2; CX36; connexin-36); gap junction protein g1 45 kDa (GJC1; CX45) In vitro and mouse...